LGT Fund Management Co Ltd. Has $3.95 Million Holdings in Zoetis Inc. $ZTS

LGT Fund Management Co Ltd. boosted its stake in Zoetis Inc. (NYSE:ZTS) by 1,273.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,434 shares of the company’s stock after purchasing an additional 31,000 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Zoetis were worth $3,952,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Global Assets Advisory LLC bought a new stake in shares of Zoetis in the 1st quarter valued at about $38,000. International Assets Investment Management LLC increased its stake in Zoetis by 24.9% in the first quarter. International Assets Investment Management LLC now owns 4,885 shares of the company’s stock valued at $573,000 after purchasing an additional 973 shares in the last quarter. Associated Banc Corp raised its holdings in Zoetis by 9.9% in the first quarter. Associated Banc Corp now owns 75,959 shares of the company’s stock worth $8,979,000 after purchasing an additional 6,842 shares during the period. Valmark Advisers Inc. boosted its position in shares of Zoetis by 7.7% during the first quarter. Valmark Advisers Inc. now owns 1,747 shares of the company’s stock worth $207,000 after purchasing an additional 125 shares in the last quarter. Finally, Pittenger & Anderson Inc. boosted its position in shares of Zoetis by 28.2% during the first quarter. Pittenger & Anderson Inc. now owns 77,265 shares of the company’s stock worth $9,133,000 after purchasing an additional 16,975 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.5%

Shares of NYSE ZTS traded up $0.41 during mid-day trading on Friday, hitting $75.49. The company had a trading volume of 5,157,373 shares, compared to its average volume of 6,410,874. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The firm has a 50-day simple moving average of $79.96 and a two-hundred day simple moving average of $107.76. The company has a market capitalization of $31.65 billion, a PE ratio of 12.52, a price-to-earnings-growth ratio of 1.18 and a beta of 0.75. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the business earned $1.48 EPS. The business’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. HSBC decreased their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, July 6th. JPMorgan Chase & Co. dropped their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. TD Cowen cut their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Finally, Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and an average target price of $123.46.

Insider Transactions at Zoetis

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Multiple law firms, including Rosen, Glancy Prongay, Bragar Eagel & Squire, The Gross Law Firm, Kessler Topaz, Schall, Howard G. Smith, and Bernstein Liebhard, are urging investors who bought ZTS shares during the class period to contact them before the July 27 lead plaintiff deadline.
• Negative Sentiment: A class action lawsuit has been filed against Zoetis and certain officers, with allegations of material misstatements and/or omissions tied to product adoption, which may increase legal costs and pressure the stock. Article Title

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.